Semax, synthetic ACTH(4–10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats

• Published in: Neuropeptides (Edinburgh) 2021-04, Vol.86, p.102114-102114, Article 102114
• Main Authors: Glazova, Nataliya Yu, Manchenko, Daria M., Volodina, Maria A., Merchieva, Svetlana A., Andreeva, Ludmila A., Kudrin, Vladimir S., Myasoedov, Nikolai F., Levitskaya, Natalia G.
• Format: Article
• Language: English
• Subjects: ACTH(4–10) analogue; Adrenocorticotropic hormone; Amines; Antidepressants; Anxiety; Biogenic amines; Brain; Fluvoxamine; Genetic crosses; Juveniles; Learning; Long-term effects; Mental depression; Monoamines; Neonatal administration; Neonates; Neuroprotection; Perinatal exposure; Placenta; Pregnancy; Rodents; Selective serotonin reuptake inhibitors; Semax; Serotonin uptake inhibitors
• ISSN: 0143-4179; 1532-2785
• DOI: 10.1016/j.npep.2020.102114

Selective serotonin reuptake inhibitors (SSRI) are commonly used to treat depression during pregnancy. SSRIs cross the placenta and may influence the maturation of the foetal brain. Clinical and preclinical findings suggest long-term consequences of SSRI perinatal exposure for the offspring. The mechanisms of SSRI effects on developing brain remain largely unknown and there are no directional approaches for prevention of the consequences of maternal SSRI treatment during pregnancy. The heptapeptide Semax (MEHFPGP) is a synthetic analogue of ACTH(4–10) which exerts marked nootropic and neuroprotective activities. The aim of the present study was to investigate the long-term effects of neonatal exposure to the SSRI fluvoxamine (FA) in white rats. Additionally, the study examined the potential for Semax to prevent the negative consequences of neonatal FA exposure. Rat pups received FA or vehicle injections on postnatal days 1–14, a time period equivalent to 27–40 weeks of human foetal age. After FA treatment, rats were administered with Semax or vehicle on postnatal days 15–28. During the 2nd month of life, the rats underwent behavioural testing, and monoamine levels in brain structures were measured. It was shown that neonatal FA exposure leads to the impaired emotional response to stress and novelty and delayed acquisition of food-motivated maze task in adolescent and young adult rats. Furthermore, FA exposure induced alterations in the monoamine levels in brains of 1- and 2- month-old rats. Semax administration reduced the anxiety-like behaviour, improved learning abilities and normalized the levels of brain biogenic amines impaired by the FA exposure. The results demonstrate that early-life FA exposure in rat pups produces long-term disturbances in their anxiety-related behaviour, learning abilities, and brain monoamines content. Semax exerts a favourable effect on behaviour and biogenic amine system of rats exposed to the antidepressant. Thus, peptide Semax can prevent behavioural deficits caused by altered 5-HT levels during development.